Rebuilding Pharmacy Benefit Integrity: The Role of Transparent Rebate Administration in Oncology

Pharmacy benefit governance is facing a pressure test. Rising drug costs, especially in oncology, coupled with increasing regulatory attention and a growing demand for accountability, have reshaped how health plan fiduciaries must approach benefit design. The strain of high-cost emerging cell and gene therapies and specialty drugs for oncology are burdensome for virtually every self-insured stakeholder.